Investor Presentaiton
7
INOVIO's Technology Advantages
Clinical Efficacy
Demonstrated clinical efficacy in Phase 2b study
Lead candidate VGX-3100 in Phase 3 for precancerous cervical dysplasia
Safety
•
Favorable safety profile tested in over 2,000 patients and over 7,000 administrations
Carries no potential toxicity from viral vectors
Versatility and Boosting
•
•
Targets virtually any antigenic sequence; combining multi-antigens into single vial
Initiated first-in-human study of optimized dMAb TM plasmid
No anti-vector response - allows for effective boosting
Rapid and Scalable Manufacturing
•
•
"Off-the-shelf" product; no frozen storage issues (room temp storage >1 yr.)
Rapid development from concept to human in <3 months (COVID-19 vaccine)
Relatively inexpensive to manufacture; produce large quantities
INOVIO
POWERING DNA MEDICINESView entire presentation